Search

Your search keyword '"Cortes, Jorge E."' showing total 3,007 results
Start Over Author "Cortes, Jorge E." Journal blood
3,007 results on '"Cortes, Jorge E."'

1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Author

Arber, Daniel A., Orazi, Attilio, Hasserjian, Robert P., Borowitz, Michael J., Calvo, Katherine R., Kvasnicka, Hans-Michael, Wang, Sa A., Bagg, Adam, Barbui, Tiziano, Branford, Susan, Bueso-Ramos, Carlos E., Cortes, Jorge E., Dal Cin, Paola, DiNardo, Courtney D., Dombret, Hervé, Duncavage, Eric J., Ebert, Benjamin L., Estey, Elihu H., Facchetti, Fabio, Foucar, Kathryn, Gangat, Naseema, Gianelli, Umberto, Godley, Lucy A., Gökbuget, Nicola, Gotlib, Jason, Hellström-Lindberg, Eva, Hobbs, Gabriela S., Hoffman, Ronald, Jabbour, Elias J., Kiladjian, Jean-Jacques, Larson, Richard A., Le Beau, Michelle M., Loh, Mignon L.-C., Löwenberg, Bob, Macintyre, Elizabeth, Malcovati, Luca, Mullighan, Charles G., Niemeyer, Charlotte, Odenike, Olatoyosi M., Ogawa, Seishi, Orfao, Alberto, Papaemmanuil, Elli, Passamonti, Francesco, Porkka, Kimmo, Pui, Ching-Hon, Radich, Jerald P., Reiter, Andreas, Rozman, Maria, Rudelius, Martina, Savona, Michael R., Schiffer, Charles A., Schmitt-Graeff, Annette, Shimamura, Akiko, Sierra, Jorge, Stock, Wendy A., Stone, Richard M., Tallman, Martin S., Thiele, Jürgen, Tien, Hwei-Fang, Tzankov, Alexandar, Vannucchi, Alessandro M., Vyas, Paresh, Wei, Andrew H., Weinberg, Olga K., Wierzbowska, Agnieszka, Cazzola, Mario, Döhner, Hartmut, and Tefferi, Ayalew

Published
2022
Full Text
View/download PDF

2. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Author

Cortes, Jorge E, Tallman, Martin S, Schiller, Gary J, Trone, Denise, Gammon, Guy, Goldberg, Stuart L, Perl, Alexander E, Marie, Jean-Pierre, Martinelli, Giovanni, Kantarjian, Hagop M, and Levis, Mark J

Subjects
Clinical Research, Rare Diseases, Hematology, Childhood Leukemia, Pediatric Research Initiative, Clinical Trials and Supportive Activities, Cancer, Pediatric, Pediatric Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, Benzothiazoles, Dose-Response Relationship, Drug, Female, Gastrointestinal Diseases, Gene Duplication, Heart Diseases, Hematologic Diseases, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Male, Middle Aged, Oncogene Proteins, Fusion, Phenylurea Compounds, Protein Kinase Inhibitors, Salvage Therapy, Tandem Repeat Sequences, Young Adult, fms-Like Tyrosine Kinase 3, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

This randomized, open-label, phase 2b study (NCT01565668) evaluated the efficacy and safety of 2 dosing regimens of quizartinib monotherapy in patients with relapsed/refractory (R/R) FLT3-internal tandem duplication (ITD)-mutated acute myeloid leukemia (AML) who previously underwent transplant or 1 second-line salvage therapy. Patients (N = 76) were randomly assigned to 30- or 60-mg/day doses (escalations to 60 or 90 mg/day, respectively, permitted for lack/loss of response) of single-agent oral quizartinib dihydrochloride. Allelic frequency of at least 10% was defined as FLT3-ITD-mutated disease. Coprimary endpoints were composite complete remission (CRc) rates and incidence of QT interval corrected by Fridericia's formula (QTcF) of more than 480 ms (grade 2 or greater). Secondary endpoints included overall survival (OS), duration of CRc, bridge to transplant, and safety. CRc rates were 47% in both groups, similar to earlier reports with higher quizartinib doses. Incidence of QTcF above 480 ms was 11% and 17%, and QTcF above 500 ms was 5% and 3% in the 30- and 60-mg groups, respectively, which is less than earlier reports with higher doses of quizartinib. Median OS (20.9 and 27.3 weeks), duration of CRc (4.2 and 9.1 weeks), and bridge to transplant rates (32% and 42%) were higher in the 60-mg groups than in the 30-mg group. Dose escalation occurred in 61% and 14% of patients in the 30- and 60-mg groups, respectively. This high clinical activity of quizartinib at the evaluated doses is consistent with previous reports with an improved safety profile. Need to dose-escalate more than half of patients who received quizartinib 30 mg also supports further investigation of treatment with quizartinib 60 mg/day.

Published
2018

3. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Author

Masarova, Lucia, Verstovsek, Srdan, Hidalgo-Lopez, Juliana E., Pemmaraju, Naveen, Bose, Prithviraj, Estrov, Zeev, Jabbour, Elias J., Ravandi-Kashani, Farhad, Takahashi, Koichi, Cortes, Jorge E., Ning, Jing, Ohanian, Maro, Alvarado, Yesid, Zhou, Lingsha, Pierce, Sherry, Gergis, Romany, Patel, Keyur P., Luthra, Rajyalakshmi, Kadia, Tapan M., DiNardo, Courtney D., Borthakur, Gautam, Bhalla, Kapil, Garcia-Manero, Guillermo, Bueso-Ramos, Carlos E., Kantarjian, Hagop M., and Daver, Naval

Published
2018
Full Text
View/download PDF

4. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Author

Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

7. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Author

Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., and Branford, Susan

Published
2016
Full Text
View/download PDF

9. Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Author

Cortes, Jorge E., primary, Hughes, Timothy, additional, Geissler, Jan, additional, Kim, Dong-Wook, additional, Lomaia, Elza, additional, Mayer, Jiri, additional, Turkina, Anna G., additional, Hurwicz Kogut, Sarah, additional, Torres Cardoso, Ana Paula, additional, Sura, Monali, additional, and Saglio, Giuseppe, additional

Published
2022
Full Text
View/download PDF

10. Long-Term Results of the Treatment of Adolescents and Adults with Acute Lymphoblastic Leukemia with a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience

Author

García-Villaseñor, Elizabeth, primary, Cortes, Jorge E., additional, Reyes-Cisneros, Oscar A., additional, Fernández-Gutiérrez, José Antonio, additional, Sánchez-Bonilla, Daniela, additional, Bojalil-Álvarez, Lorena, additional, Murrieta-Álvarez, Iván, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz Argüelles, Guillermo José, additional

Published
2022
Full Text
View/download PDF

11. Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Author

Mauro, Michael, primary, Paquette, Ronald, additional, Hehlmann, Rüdiger, additional, Williams, Loretta A., additional, Goldberg, Stuart L., additional, Michallet, Mauricette, additional, Gambacorti-Passerini, Carlo, additional, Tang, Derek, additional, DeGutis, Irene S., additional, McBride, Ali, additional, Parsons, Lori, additional, Montelongo, Monica Z., additional, and Cortes, Jorge E., additional

Published
2022
Full Text
View/download PDF

13. A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Author

Ong, Faustine, primary, Garcia-Manero, Guillermo, additional, Montalban-Bravo, Guillermo, additional, Alvarado, Yesid, additional, Ohanian, Maro, additional, Konopleva, Marina, additional, Jabbour, Elias, additional, Jain, Nitin, additional, Borthakur, Gautam, additional, DiNardo, Courtney D., additional, Daver, Naval, additional, Issa, Ghayas C., additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Takahashi, Koichi, additional, Andreeff, Michael, additional, Muftuoglu, Muharrem, additional, Delumpa, Ricardo, additional, Mayor, Ejiroghene, additional, Loiselle, Christopher, additional, Waller, Lourdes, additional, Banks, Glenda, additional, Kantarjian, Hagop, additional, Cortes, Jorge E., additional, and Short, Nicholas, additional

Published
2022
Full Text
View/download PDF

14. Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Author

Cortes, Jorge E., primary, Goldberg, Stuart L., additional, Paquette, Ronald, additional, Williams, Loretta A., additional, Hehlmann, Rüdiger, additional, Michallet, Mauricette, additional, Gambacorti-Passerini, Carlo, additional, Tang, Derek, additional, DeGutis, Irene S., additional, McBride, Ali, additional, Parsons, Lori, additional, Montelongo, Monica Z., additional, and Mauro, Michael, additional

Published
2022
Full Text
View/download PDF

16. Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Author

Cortes, Jorge E., primary, Jiang, Qian, additional, Wang, Jianxiang, additional, Weng, Jianyu, additional, Zhu, Huanling, additional, Liu, Xiaoli, additional, Hochhaus, Andreas, additional, Kim, Dong-Wook, additional, Radich, Jerald, additional, Savona, Michael R., additional, Martin-Regueira, Patricia, additional, Sy, Oumar, additional, and Saglio, Giuseppe, additional

Published
2022
Full Text
View/download PDF

17. Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial

Author

Schlenk, Richard F., primary, Montesinos, Pau, additional, Romero-Aguilar, Antonio, additional, Vrhovac, Radovan, additional, Patkowska, Elżbieta, additional, Kim, Hee-Je, additional, Zak, Pavel, additional, Wang, Po-Nan, additional, Hanyok, James, additional, Liu, Li, additional, Kamel, Yasser Mostafa, additional, Benzohra, Aziz, additional, Lesegretain, Arnaud, additional, Cortes, Jorge E., additional, Sekeres, Mikkael A., additional, Dombret, Hervé, additional, Amadori, Sergio, additional, Wang, Jianxiang, additional, Perl, Alexander E., additional, Levis, Mark J., additional, and Erba, Harry P., additional

Published
2022
Full Text
View/download PDF

18. ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Author

Hughes, Timothy, primary, Cortes, Jorge E., additional, Takahashi, Naoto, additional, Larson, Richard A., additional, Issa, Ghayas C., additional, Bombaci, Felice, additional, Ramscar, Nicholas, additional, Kapoor, Shruti, additional, Ifrah, Sophie, additional, and Hochhaus, Andreas, additional

Published
2022
Full Text
View/download PDF

20. A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Author

Radich, Jerald P., primary, Kok, Chung Hoow, additional, Chelysheva, Ekaterina Yu., additional, Cortes, Jorge E., additional, Jiang, Qian, additional, Mauro, Michael, additional, Milojkovic, Dragana, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Ongondi, Matilda, additional, Pagnano, Katia B, additional, Žácková, Daniela, additional, Rea, Delphine, additional, Evans, Nicola, additional, and Hughes, Timothy, additional

Published
2022
Full Text
View/download PDF

21. ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Author

Sasaki, Koji, primary, Mauro, Michael, additional, Levy, Moshe Yair, additional, Atallah, Ehab L., additional, Koller, Paul B., additional, Maegawa, Rodrigo, additional, Damon, Andrea, additional, Kumar, Julie, additional, Khan, Mahmudul, additional, and Cortes, Jorge E., additional

Published
2022
Full Text
View/download PDF

22. Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Author

Cortes, Jorge E., primary, Fenaux, Pierre, additional, Yee, Karen, additional, Recher, Christian, additional, Wei, Andrew H., additional, Montesinos, Pau, additional, Taussig, David C, additional, Pigneux, Arnaud, additional, Braun, Thorsten, additional, Curti, Antonio, additional, Grove, Carolyn, additional, Jonas, Brian A., additional, Khwaja, Asim, additional, Peterlin, Pierre, additional, Polyanskaya, Olga, additional, Sweeney, Jennifer, additional, Brevard, Julie, additional, Barrett, Emma, additional, and De Botton, Stephane, additional

Published
2022
Full Text
View/download PDF

23. Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Author

Cortes, Jorge E., primary, Deininger, Michael W., additional, Lomaia, Elza, additional, Moiraghi, Beatriz, additional, Sutton, Maria Undurraga, additional, Pavlovsky, Carolina, additional, Chuah, Charles, additional, Sacha, Tomasz, additional, Lipton, Jeffrey H., additional, McCloskey, James, additional, Hochhaus, Andreas, additional, Rousselot, Philippe, additional, Rosti, Gianantonio, additional, de Lavallade, Hugues, additional, Rojas, Christine, additional, Turkina, Anna, additional, Maness, Lori, additional, Talpaz, Moshe, additional, Mauro, Michael, additional, Lu, Vickie, additional, Vorog, Alexander, additional, and Apperley, Jane F., additional

Published
2022
Full Text
View/download PDF

24. Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Author

Jabbour, Elias, primary, Sasaki, Koji, additional, Issa, Ghayas C., additional, Haddad, Fadi, additional, Garcia-Manero, Guillermo, additional, Kadia, Tapan M., additional, Wierda, William G., additional, Yilmaz, Musa, additional, DiNardo, Courtney D., additional, Skinner, Jeffrey, additional, Pemmaraju, Naveen, additional, Dellasala, Sara E, additional, Pierce, Sherry A., additional, Cortes, Jorge E., additional, and Kantarjian, Hagop, additional

Published
2022
Full Text
View/download PDF

25. Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Author

Atallah, Ehab L., primary, Visotcky, Alexis, additional, Flynn, Kathryn E, additional, Zhang, Mei-Jie, additional, Radich, Jerald P., additional, Yang, Jay, additional, Oehler, Vivian G., additional, Tantravahi, Srinivas K., additional, Smith, B. Douglas Douglas, additional, Pinilla Ibarz, Javier, additional, Sweet, Kendra, additional, Mauro, Michael, additional, Druker, Brian J., additional, Thompson, James E., additional, Maldonado-Schmidt, Sonia, additional, Baim, Arielle, additional, Schiffer, Charles A., additional, Kota, Vamsi K., additional, and Cortes, Jorge E., additional

Published
2022
Full Text
View/download PDF

27. Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Author

Mauro, Michael, primary, Visotcky, Alexis, additional, Flynn, Kathryn E, additional, Radich, Jerald P., additional, Yang, Jay, additional, Oehler, Vivian G., additional, Cortes, Jorge E., additional, Kota, Vamsi K, additional, Tantravahi, Srinivas K., additional, Baim, Arielle, additional, Zhang, Mei-Jie, additional, Hinman, Alexander, additional, Atallah, Ehab L., additional, and Sweet, Kendra, additional

Published
2022
Full Text
View/download PDF

28. Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial

Author

Apperley, Jane F., primary, Cortes, Jorge E., additional, Jabbour, Elias, additional, Hochhaus, Andreas, additional, Hughes, Timothy, additional, Chuah, Charles, additional, de Lavallade, Hugues, additional, Deininger, Michael W., additional, Lipton, Jeffrey H., additional, Lomaia, Elza, additional, Maness, Lori, additional, Mauro, Michael, additional, McCloskey, James, additional, Moiraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rojas, Christine, additional, Rousselot, Philippe, additional, Sacha, Tomasz, additional, Talpaz, Moshe, additional, Turkina, Anna, additional, Sutton, Maria Undurraga, additional, Ren, Xiaowei, additional, Vorog, Alexander, additional, and Rosti, Gianantonio, additional

Published
2022
Full Text
View/download PDF

29. Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Author

Cortes, Jorge E., primary, Saikia, Tapan, additional, Kim, Dong-Wook, additional, Alvarado, Yesid, additional, Nicolini, Franck E., additional, Rathnam, Krishnakumar, additional, Khattry, Navin, additional, Punatar, Sachin, additional, Apperley, Jane F., additional, Charbonnier, Aude, additional, Deininger, Michael, additional, de Lavallade, Hugues, additional, Granacher, Nikki, additional, Gambacorti-Passerini, Carlo, additional, Lucchesi, Alessandro, additional, Mauro, Michael, additional, Vandenberghe, Peter, additional, Verhoef, Gregor, additional, Whiteley, Andrew R., additional, Nag, Arijit, additional, Apte, Shashikant, additional, Yao, Siu-Long, additional, Inamdar, Sandeep, additional, Dillu, Ruchika Irene, additional, Sreenivasan, Jayasree, additional, and Chimote, Geetanjali, additional

Published
2022
Full Text
View/download PDF

33. Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Author

Hughes, Timothy, primary, Rea, Delphine, additional, Boquimpani, Carla, additional, Minami, Yosuke, additional, Mauro, Michael, additional, Cortes, Jorge E., additional, Apperley, Jane F., additional, García Gutiérrez, Valentín, additional, Kapoor, Shruti, additional, Allepuz, Alex, additional, Quenet, Sarah, additional, Zhang, Yifan, additional, and Hochhaus, Andreas, additional

Published
2022
Full Text
View/download PDF

34. Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Author

Levis, Mark J., primary, Erba, Harry P., additional, Montesinos, Pau, additional, Vrhovac, Radovan, additional, Patkowska, Elzbieta, additional, Kim, Heeje, additional, Zak, Pavel, additional, Wang, Po-Nan, additional, Rohrbach, Jaime E. Connolly, additional, Chang, Ken CN, additional, Hanyok, James, additional, Liu, Li, additional, Kamel, Yasser Mostafa, additional, Lesegretain, Arnaud, additional, Cortes, Jorge E., additional, Sekeres, Mikkael A., additional, Dombret, Hervé, additional, Amadori, Sergio, additional, Wang, Jianxiang, additional, Schlenk, Richard F., additional, and Perl, Alexander, additional

Published
2022
Full Text
View/download PDF

35. Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Author

Padala, Sandeep Anand, primary, Vakiti, Anusha, additional, Bollag, Wendy, additional, Waller, Jennifer, additional, Kheda, Mufaddal, additional, Baer, Stephanie L, additional, Kolhe, Ravindra, additional, Mian, Mohammad A.H., additional, Jillella, Anand P., additional, Cortes, Jorge E., additional, and Kota, Vamsi, additional

Published
2022
Full Text
View/download PDF

37. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

Author

Agarwal, Anupriya, Mackenzie, Ryan J., Besson, Arnaud, Jeng, Sophia, Carey, Alyssa, LaTocha, Dorian H., Fleischman, Angela G., Duquesnes, Nicolas, Eide, Christopher A., Vasudevan, Kavin B., Loriaux, Marc M., Firpo, Eduardo, Cortes, Jorge E., McWeeney, Shannon, O’Hare, Thomas, Roberts, James M., Druker, Brian J., and Deininger, Michael W.

Published
2014
Full Text
View/download PDF

40. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Author

Baccarani, Michele, Deininger, Michael W., Rosti, Gianantonio, Hochhaus, Andreas, Soverini, Simona, Apperley, Jane F., Cervantes, Francisco, Clark, Richard E., Cortes, Jorge E., Guilhot, François, Hjorth-Hansen, Henrik, Hughes, Timothy P., Kantarjian, Hagop M., Kim, Dong-Wook, Larson, Richard A., Lipton, Jeffrey H., Mahon, François-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Pane, Fabrizio, Radich, Jerald P., Rousselot, Philippe, Saglio, Giuseppe, Saußele, Susanne, Schiffer, Charles, Silver, Richard, Simonsson, Bengt, Steegmann, Juan-Luis, Goldman, John M., and Hehlmann, Rüdiger

Published
2013
Full Text
View/download PDF

44. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Author

Kantarjian, Hagop M., Shah, Neil P., Cortes, Jorge E., Baccarani, Michele, Agarwal, Mohan B., Undurraga, María Soledad, Wang, Jianxiang, Kassack Ipiña, Juan Julio, Kim, Dong-Wook, Ogura, Michinori, Pavlovsky, Carolina, Junghanss, Christian, Milone, Jorge H., Nicolini, Franck E., Robak, Tadeusz, Van Droogenbroeck, Jan, Vellenga, Edo, Bradley-Garelik, M. Brigid, Zhu, Chao, and Hochhaus, Andreas

Published
2012
Full Text
View/download PDF

47. Targeting neuropilin-1 in human leukemia and lymphoma

Author

Karjalainen, Katja, Jaalouk, Diana E., Bueso-Ramos, Carlos E., Zurita, Amado J., Kuniyasu, Akihiko, Eckhardt, Bedrich L., Marini, Frank C., Lichtiger, Benjamin, O'Brien, Susan, Kantarjian, Hagop M., Cortes, Jorge E., Koivunen, Erkki, Arap, Wadih, and Pasqualini, Renata

Published
2011
Full Text
View/download PDF

48. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Author

Réa, Delphine, primary, Mauro, Michael J., additional, Boquimpani, Carla, additional, Minami, Yosuke, additional, Lomaia, Elza, additional, Voloshin, Sergey, additional, Turkina, Anna, additional, Kim, Dong-Wook, additional, Apperley, Jane F., additional, Abdo, Andre, additional, Fogliatto, Laura Maria, additional, Kim, Dennis Dong Hwan, additional, le Coutre, Philipp, additional, Saussele, Susanne, additional, Annunziata, Mario, additional, Hughes, Timothy P., additional, Chaudhri, Naeem, additional, Sasaki, Koji, additional, Chee, Lynette, additional, García-Gutiérrez, Valentin, additional, Cortes, Jorge E., additional, Aimone, Paola, additional, Allepuz, Alex, additional, Quenet, Sara, additional, Bédoucha, Véronique, additional, and Hochhaus, Andreas, additional

Published
2021
Full Text
View/download PDF

49. Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Author

Jabbour, Elias J., primary, Deininger, Michael W., additional, Abruzzese, Elisabetta, additional, Apperley, Jane F, additional, Cortes, Jorge E., additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, DiPersio, John F., additional, Hochhaus, Andreas, additional, Lipton, Jeffrey H., additional, Nicolini, Franck E., additional, Pinilla Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Rousselot, Philippe, additional, Mauro, Michael J., additional, Shah, Neil P, additional, Talpaz, Moshe, additional, Vorog, Alexander, additional, Lu, Vickie, additional, and Kantarjian, Hagop, additional

Published
2021
Full Text
View/download PDF

50. Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

Author

Deininger, Michael W., primary, Apperley, Jane F, additional, Arthur, Christopher Kevin, additional, Chuah, Charles, additional, Hochhaus, Andreas, additional, De Lavallade, Hugues, additional, Lipton, Jeffrey H., additional, Lomaia, Elza, additional, McCloskey, James K, additional, Maness, Lori J., additional, Mauro, Michael J., additional, Moiraghi, Beatriz, additional, Pavlovsky, Carolina, additional, Rosti, Gianantonio, additional, Rousselot, Philippe, additional, Undurraga, Soledad S., additional, Lu, Vickie, additional, Vorog, Alexander, additional, and Cortes, Jorge E., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results